Trials / Terminated
TerminatedNCT02669849
Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury
A Phase 2b/3, Double-blind, Randomized, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of VX-210 in Subjects With Acute Traumatic Cervical Spinal Cord Injury
- Status
- Terminated
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Vertex Pharmaceuticals Incorporated · Industry
- Sex
- All
- Age
- 14 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the efficacy and safety of VX-210 in subjects with Acute Traumatic Cervical Spinal Cord Injury. Secondary objectives include the specific evaluation of the effects of VX-210 on neurological recovery and daily function after spinal cord injury.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | VX-210 | |
| DRUG | Placebo |
Timeline
- Start date
- 2016-07-01
- Primary completion
- 2018-11-01
- Completion
- 2018-11-01
- First posted
- 2016-02-01
- Last updated
- 2020-01-22
- Results posted
- 2020-01-22
Locations
39 sites across 2 countries: United States, Canada
Source: ClinicalTrials.gov record NCT02669849. Inclusion in this directory is not an endorsement.